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DOI 10.1016/j.ccr.2010.09.005SUMMARYInmultiplemyeloma (MM), an incurable B cell neoplasm,mutation or deletion of p53 is rarely detected at diag-
nosis. Using small-molecule inhibitors of MDM2, we provide evidence that miR-192, 194, and 215, which are
downregulated in a subset of newly diagnosed MMs, can be transcriptionally activated by p53 and then
modulate MDM2 expression. Furthermore, ectopic re-expression of these miRNAs in MM cells increases
the therapeutic action of MDM2 inhibitors in vitro and in vivo by enhancing their p53-activating effects. In
addition, miR-192 and 215 target the IGF pathway, preventing enhanced migration of plasma cells into
bone marrow. The results suggest that these miRNAs are positive regulators of p53 and that their downregu-
lation plays a key role in MM development.INTRODUCTION
The tumor suppressor p53 is frequently inactivated bymutations
or deletions in cancer. p53 acts as a potent transcription factor
and can be activated in response to diverse stresses, leading
to induction of cell-cycle arrest, apoptosis, or senescence (Junt-
tila and Evan, 2009; Xue et al., 2007). Although regulation of theSignificance
Therapeutic activation of p53may be particularly appropriate fo
intact TP53. We describe a signaling pathway in which miR-19
latory loop, controlling the balance between p53 and MDM2
promoter in MM cell lines suggests that epigenetic downreg
mRNA and protein expression, decreases the ability of p53 to d
loop in favor of MDM2. Exploring these miRNAs as enhancers
cells might open avenues for miRNA-targeted therapies and M
Cp53 pathway is not fully understood at the molecular level, it has
been well established that activated p53 suppresses cancer
progression, underlining why cancer cells have developed
multiple mechanisms to disable p53 function (Danovi et al.,
2004; Ventura et al., 2007). In human tumors that retain wild-
type (WT) p53 (Junttila and Evan, 2009; Lane, 2001) p53 can
be antagonized by murine double minute 2 (MDM2), a negativer treatment of the50%of hematopoieticmalignancies with
2, 194, and 215 are regulators of the MDM2/p53 auto regu-
expression. Hypermethylation of the miR-194-2-192 cluster
ulation of these miRNAs, which leads to increased MDM2
ownmodulate MDM2 expression, thus tipping the regulatory
in the pharmacological activation of the p53 pathway in MM
M treatment.
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offering a therapeutic strategy (Dickens et al., 2009; Brown
et al., 2009). It has been reported that inhibiting MDM2 expres-
sion can reactivate p53 in cancer cells, leading to their demise
(Dickens et al., 2009; Saha and Chang, 2010).
TP53mutation is rarely detected at diagnosis inmany hemato-
logical cancers such as multiple myeloma (MM), acute myeloid
leukemia, chronic lymphocytic leukemia, and Hodgkin’s disease
(HD). Thus, numerous reports have shown that therapeutic
induction of p53 might be particularly suitable for the treatment
of hematological malignancies (Saha and Chang, 2010). Among
them, multiple myeloma (MM) is a currently incurable plasma cell
proliferative disorder that results in considerable morbidity and
mortality (Kuehl and Bergsagel, 2002; Fonseca et al., 2009).
MM develops from a benign condition called monoclonal
gammopathy of undetermined significance (MGUS) (Weiss
et al., 2009). Individuals with MGUS often remain stable for years
and do not require treatment. However, for unknown reasons,
this benign condition can evolve into MM at a rate of 1% per
year, with some MMs developing after many years (Kuehl and
Bergsagel, 2002; Fonseca et al., 2009).
In MGUS and in the majority of newly diagnosed MM cases
TP53 is WT (Kuehl and Bergsagel, 2002; Chng et al., 2007) and
the protein is rarely detectable (Stuhmer and Bargou, 2006).
Interestingly, in MM cells, expression of p53 protein levels can
be rescued by antagonizing MDM2. Several reports have
focused on the p53-mediated apoptotic pathway, upon endog-
enous p53 protein re-expression by the small-molecule MDM2
antagonists (Nutlins) and target genes which may be involved
in p53-dependent apoptosis in MM cells have been identified
(Stuhmer and Bargou, 2006).
MicroRNAs are an abundant class of short, non-protein-
coding RNAs that mediate the regulation of target genes post-
transcriptionally and that have emerged as master regulators in
diverse physiologic and pathologic processes (Bartel, 2004),
and oncogenesis (Croce, 2008). Recently, microRNAs (miRNAs)
have been reported to be directly transactivated by p53
(He et al., 2007). miRNAs have also been shown to target p53
and/or components of p53 regulatory pathways, thereby directly
and/or indirectly affecting its activities (Park et al., 2009; Zhang
et al., 2009). We previously published the global miRNA-expres-
sion profiles of MM and MGUS and contrasted these profiles
with those of normal plasma cells (PCs) (Pichiorri et al., 2008).
The findings defined a miRNA signature related to expression
and regulation of proteins associated withmalignant transforma-
tion of PCs, such as p53 (Pichiorri et al., 2008). We have now
examined the regulation and functional roles of miRNAs in MM
development using small-molecule inhibitors of MDM2.
RESULTS
Identification of p53-Regulated miRNAs in MM
To determine if miRNAs are regulated by p53 in MM cells, we
performed custom microarray analysis with an expanded set of
probes capable of assaying the expression of more than
500 human miRNAs. Two approaches to compare the effect of
p53 level on miRNA expression were used. We first assessed
a specific signature associated with the presence of WT TP53
in MM cell lines as shown in Figure 1A and Table S1 available on-368 Cancer Cell 18, 367–381, October 19, 2010 ª2010 Elsevier Inc.line. Six MM cell lines were used in the analyses: MM1s, NCI-
H929, and KMS28BM which retain and express WT TP53;
RPMI-8226, U266 with mutant TP53; and JJN3 that does not
express TP53mRNA. Western blot analysis of these cells shows
their p53 and MDM2 steady-state protein levels, respectively
(Figure S1A). Genomic and cDNA sequence analyses confirmed
the presence of WT TP53 cells in association with higherMDM2
mRNA expression (Figure S1B). Several differentially expressed
miRNAs were identified (Table S1). Some of these miRNAs, such
as those ofmiR-34 family, have been found to be associatedwith
p53 status in other human malignancies (Hermeking, 2010).
In the second approach, we performed miRNA microarray anal-
ysis in MM1s cells treated with or without Nutlin-3a (10 mM),
a small-molecule inhibitor of MDM2 (Figure 1B). In response to
Nutlin-3a treatment, we identified expression of distinct miRNAs
associated with p53 activation (Figure 1B; Table S2). Only two
miRNAs were upregulated in both analyses: miR-34a and
miR-194 (Figures 1A and 1B; Tables S1 and S2). These results
not only confirm upregulation of miR-34a as a function of wild-
type (WT) p53 status (He et al., 2007) but also point to strong
upregulation of miR-194 by p53 (Tables S1 and S2; Figures 1A
and 1B). The significant upregulation of miR-192 and miR-215
after p53 re-expression through Nutlin-3a treatment is especially
interesting because they are located, together with miR-194, in
two related microRNA clusters, the miR-194-2-192 cluster at
11q13.1 and the miR-215-194-1 cluster at 1q41.1 (Table S2),
and have the same seed sequence. Genomic locations of these
two clusters have been reported to be important for MM
(Fonseca et al., 2009). miR-194 also has the same mature
sequence regardless its expression cluster and miRNAs of the
same cluster are usually expressed together (Garofalo et al.,
2009; Ventura et al., 2008).
p53 Induces the Expression of miR-192, 194, and 215
To confirm the microarray data, we first tested by q-RT-PCR for
the presence of miR-34a, miR-194, and its cluster associate,
miR-192 and 215, in WT TP53 compared with Mut TP53 cells
(Figure S1C). WT TP53 cells retained higher expression of
miR-34a, miR-194, and miR-192 (Figure S1C), but did not show
expression of miR-215, suggesting that the 11q13.1 miR-194-
2-192 cluster is associated with WT TP53 status in MM cells.
To determine the kinetics of p53 activation, we treated MM1s
cells with 10 mM Nutlin-3a for different duration of time. p53
was barely detectable by immunoblotting at 6 hr but increased
after 12, 18, and 24 hr of treatment and remain constant at 30–
36 hr (Figure 1C). The induction of p53 was also associated
with MDM2 accumulation, p21 expression, and c-MYC downre-
gulation after 12 hr of treatment (Figure 1C). The expression of
p21-encoding CDKN1A, a p53 target gene, was also assessed
by RT-PCR (Figure 1D). By northern blot and qRT-PCR analysis,
we also studied the kinetics of miRNA activation during p53 up-
modulation in MM1s cells. The kinetics of miR-34a, miR-194,
miR-192, and miR-215 expression (Figure 1E) were directly
correlated with p53 protein upregulation and p21 activation
(Figures 1C and 1D), while for miR-15 and miR-29a/b the
dynamics of expression appeared more related to downregula-
tion of their repressor c-MYC as expected (Chang et al., 2008;
Figures S1D and S1E; Figure 1D), than to p53 activation. To
confirm the responsiveness of these miRNAs to p53, cell lines
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Figure 1. Identification of p53-Regulated miRNAs in MM Cells
(A) Overview of two-way (genes against samples) hierarchical cluster (Euclidean distance) of 6 MM cell lines in duplicate using the genes that vary the most
between samples. As shown, the clustering is mainly determined by the presence of WT TP53 expression (NCI-H929, MM1s, and KMS28BM) or mutant/null
TP53 (U266, RPMI-8226, JJN3) in the cell lines. In magnification are reported the miRNAs upregulated more than 3-fold in WT TP53 cell lines with p < 0.001.
See also Figure S1 and Table S1.
(B) Overview of two-way ofMM1s cells treatedwith 10 mMNutlin-3a overnight (biological quadruplicate) andwith DMSO (biological triplicate) using the genes that
vary the most between samples. As shown, the clustering is mainly determined from the Nutlin-3a treatments and DMSO treatment. Color areas indicate relative
expression of each gene with respect to the genemedian expression (red above, green below the median value, and black, samples with signal intensity to back-
ground of 2 or less). See also Figure S1 and Table S2.
(C and D) Western blot analysis of p53, MDM2, phosphor(p)-MDM2, c-MYC, p21, and Gapdh (C) and time course of CDKN1A mRNA expression by RT-PCR in
Nutlin-3a-treated (10 mM)MM1s cells (D). The PCRproductswere normalized to ACTIN expression. Values representmean observed in four different studies ±SD.
(E) Kinetics ofmiR-194,miR-192,miR-215, andmiR-34a inMM1s cells after Nutli-3a treatment,measured by qRT-PCR and northern blot analysis. Lines represent
relative fold changes betweenDMSOandNutlin-3a treatment ±SD.RNU44 (qRT-PCR) andRNU6B (northern blot) expressionwas used for normalization. See also
Figure S1.
(F–H)miR-192,miR-215 andmiR-194 relative expression inCD138+PCs fromhealthy,MGUS, andMMsamples (see Table S3)were determined by Taqman q-RT
PCR assay. Each data sample was normalized to the endogenous reference RNU44 and RNU48 by use of the 2– ct method. The relative expression values were
used to design box and whisker plots. Dots in the boxes indicate outlier points. Kruskal-Wallis analysis assessed that the three miRNAs were differentially ex-
pressed among MGUS samples versus MM PCs samples of the Bartlett test p% 0.001.
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Figure 2. miR-194-2-192 Cluster Is Induced Following p53 Activation
(A) Luciferase reporter activity of promoter constructs of miR-192-194-2 cluster on chromosome 11q13.1 in MM1s cells after p53 transfection ±SD. The arrow
above construct P1 indicates the position of the transcription start site +1. p53 binding sites (BD) are indicated (blue box).
(B) Relative luciferase activity of P7 reporter construct. Themagnified sequence highlighted in blue shows the location of the El Deiry p53 consensus binding sites
in P7 construct sequence. Deletions introduced into the P7 construct are shown in yellow (X) showing abolition of the promoter activity.
(C) Chip assay after 24 hr of p53 nongenotoxic activation, showing binding of p53 to the miR-192-194-2 cluster promoter in vivo in MM1s cells.
(D) Luciferase activity of empty vector (EV), P2 and P10 reporter constructs after nongenotoxic activation of p53 andMDM-2mRNA silencing. Luciferase activities
were normalized by Renilla luciferase activities. Values represent mean ± SD from three experiments.
See also Figure S2.
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(DMSO), followed by qRT-PCR to monitor miRNA levels upon
p53 activation (Figures S1F–S1K). Induction of miR-34a, miR-
192, miR-215, and miR-194 was detected only in the cell lines
treated with Nutlin-3a and harboring WT TP53 (p < 0.001,
Figure S1). Next,we analyzed induction of thesemiRNAs, byNut-
lin-3a in freshly isolated CD-138+ PCs (Figure S1L), from eight
bone marrow aspirates of MM patients. Two samples (Pt-1 and
Pt-2) exhibited TP53 deletion by FISH analysis, while 6 (Pt-3 to
Pt-8) retained TP53 genes (Table S3). We detected induction of
p53, miR-34a, 192, 194, 215 after 12 hr of Nutlin-3a treatment
(Figures S1M–S1O) in TP53 WT samples, in association with
different levels of CDKN1A mRNA activation (Figure S1O).
Furthermore, to determine if these miRNAs are relevant in MM
pathogenesis, we analyzed the expression of miR-194, 192,
and 215 in a panel of CD138+ PCs obtained from newly diag-
nosed MM patients (n = 33), MGUS (n = 14) patients and normal
donors (n = 4) (Table S3) by qRT-PCR (Figures 1F–1H). Through
Kruskal-Wallis analysis, we found that these clusters of miRNAs
are consistently downregulated in MM samples (p < 0.001)
compared with MGUS samples.370 Cancer Cell 18, 367–381, October 19, 2010 ª2010 Elsevier Inc.Identification of the p53 Core Element
in the pri-miR-192-194-2 Promoter at 11q13.1
To determine if p53 is directly involved in the transcriptional regu-
lation of miR-194-2-192 and miR-215-194-1 clusters, we
analyzed the cluster promoter regions. The upstream genomic
region close to the transcription start site (TSS) (+1) (Hino
et al., 2008) of pri-miR-194-2-192 contains several highly
conserved regions among human, mouse, rat, and dog
sequences (from 162 to +21 with respect to the TSS). To iden-
tify the promoter region responsive to p53 re-expression, we
constructed reporter plasmids carrying various genomic se-
quences around the TSS of the pri-miR-194-2-192 cluster and
subjected them to luciferase assay (Figure 2A). Bioinformatics
search identified a previously reported high score p53
consensus site between 900/912 bp (Sinha et al., 2008;
Song et al., 2008); however, this site was not functional for p53
activation since luciferase reporter constructs excluding this
region retained full activity (P3-P7) (Figure 2A). The region
from 245 to +186 bp (P7) had promoter activity comparable
to that of the longest regions in MM cells after forced expression
of p53 (Figure 2A), but regions from 125 to +186 bp (P8)
Cancer Cell
miR-192, 194, and 215 Target MDM2 in Myeloma Cellsand912 to 245 bp (P10) did not. We identified a p53-respon-
sive element between 245 and 125 bp (Figure 2B) because
the construct excluding this region was not affected by p53
expression (Figure 2A). Since conserved regions in a given
gene promoter are expected to contain regulatory elements,
we focused on the highly conserved region controlling luciferase
activity, the region between 161 and 135 bp. Luciferase
assay using a construct mutated for each C and G contained
in the two decamers of the hypothetical El-Deiry consensus
sequence revealed that this unpredicted and previously unpub-
lished region is critical for p53 transcriptional activation of the
pri-miR-194-2-192 cluster (Figure 2B). Indeed, we found that
endogenous p53 directly interacts with the core element of
the pri-miR-194-2 promoter in MM1s cells, as demonstrated
by CHIP assay after 12 hr of Nutlin-3a treatment (Figure 2C).
As a positive control, we used the p53 consensus site on the
miR-34a promoter, while a nonspecific sequence served as
negative control (Figure 2C). Ectopic expression of p53 activated
the promoter of both members of the pri-miR-194-2-192 cluster
in MM1s cells (Figure 2D).MDM2 siRNA after p53 re-expression
in MM1s cells led to higher relative luciferase activity and thus
confirmed its dependence on p53 re-activation. Taken together,
these data suggest that p53 is a key transcriptional activator of
pri-miR-194-2 through directly binding to the core promoter
element (Figure 2D). We also attempted to identify the promoter
and primary transcript of miR-215-194-1 on chromosome
1q41.1, but could not identify the primary transcript initiation
point by 30 and 50 RACE and PCR amplification of the putative
transcribed sequences (ESTs); however, we confirmed the previ-
ously published consensus site for p53 by CHIP analysis
(Figure S2).
miR-192, 194, and 215 Affect p53-Dependent
MM Cell Growth
To examine the relevance of p53-mediated regulation of miR-
192, 194, and 215 in MM, we first tested whether reintroduction
of these miRNAs affected the biology of MM cells. Previous
studies (Georges et al., 2008; Braun et al., 2008) showed that
such reintroduction induced expression of p21 in different
cancer cell lines which carried WT TP53, with a consistent
G0/G1 arrest and p53 protein expression. The molecular mech-
anism of p53 re-expression remained elusive. To confirm this
effect in our model, miR-192, miR-194, and miR-215 were
introduced into transfection in WT TP53-cell lines (MM1s,
NCI-H929, and KMS28BM), as well as cells with mutated
TP53 (RPMI-8226), followed by detection of TP53 and mRNAs
of target genes CDKN1A and MDM2, by RT-PCR analysis
(Figure S3). We found consistent re-expression of CDKN1A in
TP53 WT cells (Figure S3A) after transfection, but did not
detect any increase in TP53 mRNA (Figure S3B). Using MTS
assay, we observed significant growth arrest in the cells trans-
fected with miR-192, 215 and a less significant arrest with miR-
194 in MM cells carrying WT TP53 (Figures 3A–3C), as
compared with scrambled sequences. In contrast, we did not
detect this effect in RPMI-8226 cells (Figure 3D) expressing
mutant TP53. Next, we determined if p53-responsive miRNAs
interfere with the clonogenic survival of MM cells. MM cells
were lentivirus-transduced with miR-192, miR-215, miR-194
and miR-34a, miR-192, and 215 in WT p53 cells suppressedCcolony formation to an extent comparable to miR-34a, which
was used as an internal control. Of note, miR-194 was less
effective than miR-215 and miR-192. These miRNAs did not
suppress colony formation in RPMI-8226 (Figures 3E and 3F)
or U266 cells (F.P., S.-S.S., C.M.C, unpublished data), while
miR-34a did exhibit colony suppression in these mutant
TP53 cells, confirming its p53-independent apoptotic action
(Hermeking, 2010).
To further explore the p53-dependent mechanism(s) of
miR-192, 215, and 194 interferences with cell growth and colony
formation, we used flow cytometry to determine if their expres-
sion affects progression through the cell cycle. We noted that
in the two WT TP53 cell lines with high expression of MDM2
mRNA, MM1s and NCI-H929 (Figure S1B), the p53-responsive
miRNAs induced a consistent G0/G1 arrest. This effect was
observed in 30% of scrambled-transfected cells versus
60% of the cells transfected with miR-192 and 215 and
45% for miR-194 (Figures 3G and 3H). By contrast in
KMS-28BM cells, retaining WT TP53 but expressing lower levels
ofMDM2 mRNA (Figure S1B), we detected increases of sub-G1
fractions (indicative of cell death) in cells transfected with
miR-192 (25% sub-G1), 215 (30%), and 194 (12%) at 48 hr after
transfection, compared with 3% in control cells transfected
with the Scr sequence (Figure 3I). At 48 hr after transfection,
we also detected increased caspase-3 activity (Figure 3J). The
differential effect of the miRNAs on TP53 WT cells carrying
lower MDM2 mRNA basal expression (Figure S1B) led us to
analyze MDM2 levels after miRNA transfection (Figure S3C).
MDM2 mRNA, but not protein, was detected after MM cells
transfection. BecauseMDM2 protein is rapidly autoubiquitinated
and degraded through the proteasome pathway (Marine and
Lozano, 2010); p53 induction is necessary for its detection in
MM cells (Stuhmer and Bargou, 2006; Ooi et al., 2009). Only in
one (Mut TP53 RPMI-8226) of six MM cell lines analyzed was
MDM2 protein detected without p53 activation (Figures S1A
and S1G). We also noted thatMDM2mRNA was downregulated
after ectopic expression of these miRNAs, mostly in WT TP53
cells, but to some extent also in Mut TP53 cells (RPMI-8226)
(Figure S3C). These data were confirmed at the protein level in
RPMI-8226 cells where we observed 20% downregulation of
MDM2 protein at 72 hr after miRNA transfection (Figure S3D).
The results indicate that ectopic expression of miR-192, 215,
and 194 in WT TP53 cells inhibits cell growth and enhances
apoptosis, effects that could be related to MDM2 regulation in
MM cells.
Human MDM2 Is a Direct Target of miR-192,
194, and 215
The data thus far demonstrate that the biological functions of
miR-192, 215, and 194 in MM cells is p53 dependent. After
introduction of these miRNAs the TP53 mRNA level did not
change in MM cells but higher CDKN1A and lower MDM2
mRNA levels were observed (Figure S3). Both genes, MDM2
and CDKN1A, are direct targets of p53 but their expression in
this case was not preceded by TP53 transcription
(Figure S3B). Thus, we hypothesized that miR-192, 194 and
215 could target the expression of MDM2. To further examine
the effects of these miRNAs on MDM2 protein expression in
WT TP53 MM cells, we analyzed the consequences of ectopicancer Cell 18, 367–381, October 19, 2010 ª2010 Elsevier Inc. 371
KMS28BM WT TP53
Scr
192
194
215
MDM2
0
50
100
150
200
250
300
350
0hr 24hr 48hr 72hr
MM1s WT TP53
0
100
200
300
400
500
600
0hr 24hr 48hr 72hr
MDM2NCI-H929 WT TP53
0
50
100
150
200
250
300
350
400
0hr 24hr 48hr 72hr 
RPMI-8226 Mut TP53
0
50
100
150
200
250
0hr 24hr 48hr 72hr
*
*
* p<0.03
*
*
* p=0.05
*
*
*
*
*
*
* p<0.0001 * p<0.0005
N
um
be
r 
o
f C
ol
o
n
ie
s
0
20
40
60
80
100
120
140
0
20
40
60
80
100
N
um
be
r 
o
f C
ol
o
n
ie
s
miR- Scr 194 192 215 34a Scr 194 192 215 34a
0
50
100
150
200
250
N
um
be
r 
o
f C
ol
o
n
ie
s
0
40
80
120
160
200
N
um
be
r 
o
f C
ol
o
n
ie
s
Scr 194 192 215 34a Scr 194 192 215 34a
Scr
194
215
192
Arrest
DNA Area
C
o
u
n
t
s
MM1s
Scr
194
192
Arrest
DNA Area
C
o
u
n
t
s
NCI-H929
KMS28BM
C
o
u
n
t
s
Scr
194
215
192
Arrest
28±2%Arrest
58±2%miR-192
G0/G1
53±3%miR-215
42±4%miR-194
30±3%Scr
215
miR-215 55±3%
10±2%Arrest
G0/G1
46±3%miR-194
33±2%Scr
60±3%miR-192
miR-192
miR-215
2.8±2%
1.2±2%
11±3%
28±5%
22±3%
Arrest
Sub-G1
Scr
miR-194
C
a
s
p
a
s
e
-
3
 
a
c
t
i
v
i
t
y
0
40
80
120
160
200
Scr 194 192 215miR-
A B
C D
E
H
I
G
J
F
MM1s NCI-H929 KMS28BM RPMI-8226
*
* *
*
* *
*
* *
*
*
* p<0.05
**p< 0.001
MM1s NCI-H929 KMS28 RPMI-8226
Scr
miR-194
miR-192
miR-215
miR-34a
C
e
l
l
 
g
r
o
w
t
h
 
(
%
)
 
C
e
l
l
 
g
r
o
w
t
h
 
(
%
)
 
C
e
l
l
 
g
r
o
w
t
h
 
(
%
)
C
e
l
l
 
g
r
o
w
t
h
 
(
%
)
DNA Area
125 μ
Figure 3. miR-192-194-215 Induce Decrease of Proliferation and Cell-Cycle Arrest in WT TP53 MM Cells
(A–D)MTS assay performed inMM1s (A), NCI-929 (B), KMS28BM (C), andRPMI-8226 (D) cell lines. Cells were transfected withmiR-192, 194, 215, and scrambled
sequence (Scr) and were harvested at 24, 48, and 72 hr after transfection. p values are indicated. See also Figure S3.
(E and F) Soft agar colony suppression assay in WT TP53 and mutant TP53 MM cell lines after miRNAs transduction by lentivectors.
(G–J) Flow cytometry analysis in MM1s (G), NCI-H929 (H), and KMS28BM (I) cells (miR-192, 194, 215, and Scr transfected) at 48 hr of transfection, after first being
arrested and synchronized in G2/M phase by Nocodazole for 16 hr. Apoptosis in KMS28BM was evaluated by caspase-3 activity (J). All experiments were
performed in triplicate ±SD.
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Cancer Cell
miR-192, 194, and 215 Target MDM2 in Myeloma Cellsexpression of miR-192, miR-194, and miR-215 at 72 hr after
transfection and 12 hr of nongenotoxic activation of p53 by
Nutlin-3a (10 mM). Increased expression of these miRs upon
transfection was confirmed by qRT-PCR (Figure S4A), and
the effects on p53, MDM2, and p21 levels were analyzed by
western blot (Figure 4A). Overexpression of miR-192, 194,
and miR-215 significantly increased the level of p53 and p21
at 12 hr after Nutlin-3a treatment compared with Scr-trans-
fected cells (p < 0.001), as shown by densitometric analysis
in Figures 4B and 4C. Expression of MDM2 protein was
dramatically decreased in both cell lines (Figures 4A–4C).
Conversely, knockdown by 20-O-me-anti-miR-192-194 and
215 (pool) after 12 hr of Nutlin-3a treatment, as confirmed by
qRT-PCR (Figure S4B) in TP53WT cell lines, increased the level
of MDM2 protein (p < 0.01), while p21 and p53 protein levels
were attenuated (p < 0.01) (Figure 4B), as confirmed by densi-
tometry (Figure 4E). We also confirmed that MDM2 mRNA
levels were strongly reduced in the miR-192-, 194-, and 215-
transfected cells at 6 and 12 hr of Nutlin-3a treatment in both
cell lines (Figures 4C). These results indicate that miR-192,
194, and 215 induce the degradation of MDM2 mRNA, confirm-
ing that they regulate both, protein and RNA levels. We next
tested whether MDM2 is a direct target of these miRNAs by
performing a bioinformatics search (Target Scan [Lewis et al.,
2003]; Pictar Pictar [Krek et al., 2005]) but were unable to iden-
tify the 30UTR of MDM2 as a target. Because the 30UTR of
MDM2 is not well conserved across species, we decided to
use the RNA22 target prediction program (Miranda et al.,
2006) which does not need validated targets for training, and
neither requires nor relies on cross-species conservation.
RNA22 predicted two miRNA-responsive elements (MREs) for
miR-192/215 and two MREs for miR-194 in the 30UTR of human
MDM2 (HDM2) (Figures 4D; Figures S4C–S4G). To verify that
HDM2 is a direct target of miR-192, miR-194, and miR-215,
HDM2 30UTR containing all MREs (4K), was cloned into
pGL3 basic construct downstream of the luciferase open
reading frame (Figure 4D). This reporter construct was used
to transfect MM1s cells which express the endogenous miRs
following upmodulated p53 expression. Increased expression
of these miRs upon transfection significantly diminished
luciferase expression (Figure 4D). We subsequently screened
the predicted MREs on the 30UTR of HDM2 mRNA, using lucif-
erase assays with four different constructs carrying the MREs
for miR-192/215 and miR-194 (Figures S4H–S4K). We
observed that expression of each specific MRE reporter
construct was specifically downregulated upon transfection of
each individual miRNA. Conversely, when we performed lucif-
erase assays using a plasmid harboring the binding sites inac-
tivated by site-directed mutagenesis, we observed a consistent
reduction in the inhibitory effects (Figures S4H–S4K). We also
analyzed the expression of MDM2 mRNA in a panel of
CD138+ PCs obtained from MM patients, MGUS patients,
and normal donors by RT-PCR (Figure 4E). Through Kruskal-
Wallis analysis, we found that MDM2 mRNA is significantly up-
regulated in MM samples (p < 0.001) compared with MGUS
samples and normal PCs (Figure 4E). Using nonparametric
test analysis, we found a significant inverse correlation between
miR-192 expression and MDM2 mRNA in MM samples (Sper-
man r = 0.698, p < 0.0001, n = 33) (Figure 4F).CmiR-192, 194, and 215 Re-expression Enhances
Sensitivity of WT TP53 MM Cells to Nongenotoxic
Activation of p53 In Vitro and In Vivo
To determine if re-expression of the miRNAs could enhance
sensitivity of WT TP53 MM cells to nongenotoxic activation
of p53, we tested MI-219, a highly selective, orally active
small-molecule inhibitor of the MDM2-p53 interaction (Shang-
ary et al., 2008). We first examined whether MI-219 induces
p53, MDM2, p21, and Puma upregulation in MM1s cells after
miR-192, miR-194, and miR-215 transfection. In cells with
forced expression of miR-192 and 215, p53 became detect-
able even in untreated cells (Figures 5A and 5B) (p < 0.05),
confirming previously published data in other cell lines
(Georges et al., 2008; Braun et al., 2008). p53 re-expression
and subsequent p21 and Puma upregulation was observed
in these cells and in miR-194-transfected cells and is clearly
visible following 24 hr of 2.5 mM MI-219 treatment
(Figure 5A). In control cells (Scr), the treatment was ineffective
(Figure 5A). Densitometric analysis of p53 and MDM2 protein
levels was performed when cells were treated for 24 hr with
2.5, 5, and 10 mM MI-219 (Figure 5B). Confirming our previous
data, we observed higher p53 accumulation (R2-fold increase,
p < 0.001) and dramatic MDM2 downregulation (R3-fold
decrease, p < 0.001) in miRNA-transfected cells (Figure 5B).
These opposing changes in MDM2 and p53 expression levels
correlated with higher activation of p53 downstream targets,
p21 and Puma (Figure 5A). Furthermore, MI-219 induced
higher caspase-3 activation in the presence of miR-192,
miR-194, and miR-215 (p < 0.001) (Figure 5C). Next, we exam-
ined whether activation of p53 by MI-219 leads to apoptosis in
MM cells. Indeed, treatment with MI-219 induced apoptosis as
revealed by Annexin V staining (Figure 5D). In cells transfected
with a pool of miRNAs, MI-219 effectively (p < 0.0002) induced
apoptosis at 2.5 mM (27% ± 3%) and 5 mM (32% ± 3%) while
the scrambled control did not. This effect was less significant
when using MI-219 at 10 mM (30% ± 5%), though it was
enhanced when treatment was combined with miRNAs
(55% ± 5%) (Figure 5D). Increased concentration of MI-219
did not increase the apoptotic rate of scrambled-transfected
cells but caused nonspecific toxicity (data not shown).
Because previous studies have shown that MI-219 achieved
excellent oral availability, we investigated if, in mouse xeno-
graft models, the combined action of miRNAs and oral
MI-219 could suppress tumorigenicity of MM cells. Viable
MM1s Gfp+/Luc+ cells (8 3 106) were injected subcutaneously
into the right flank of 40 nude mice. At 3 weeks after injection
a group of 32 mice with comparable tumor size were selected
and randomly divided into four groups for four independent
experiments, using eight mice for each combined treatment
(Figure 5E). Specifically, we used the combination of oral treat-
ment with 200 mg/kg MI-219 or vehicle control (VE) once a day
for 14 days plus direct tumor injection of double-strand RNA
scrambled sequence (Scr) or a pool of pre-miR-192, 194,
and 215 (miRs). Whereas the VE-Scr-treated tumors increased
2-fold in volume in 2 weeks (from 5390 ± 993 mm3 to 13,500 ±
3200 mm3 [p < 0.0001]), MI-219/Scr-treated tumors remained
static in volume (5390 ± 993 mm3 to 5400 ± 1200 mm3)
(Figure 5E). By contrast, mice treated with VE-miRs showed
1.5-fold reduction in tumor size (from 5390 ± 993 mm3 toancer Cell 18, 367–381, October 19, 2010 ª2010 Elsevier Inc. 373
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Figure 4. miRNA-192-194 and 215 Target MDM2 at the mRNA and Protein Levels in MM Cells
(A) MM1s and NCI-H929 cells (pre-miRNA-192, 194, 215, Scr sequence-transfected) were harvested at 72 hr after transfection and 12 hr Nutlin-3a treatment
(10 mM). Whole-cell lysates were subjected to western blotting using p53, MDM2, p21, and Gapdh antibodies. Densitometric analysis showing the effect of
miR-194 (white bars), miR-192 (gray bars), miR-215 (black bars) compared with Scr sequence (green bars) transfected cells of endogenous p53, MDM2, and
p21 in MM1s ±SD (B) and NCI-H929 (C) Nutlin-3a treated. (D) Immunoblot analysis showing p53, MDM2, and p21 protein expression after 48 hr of miR-192,
miR-194, miR-215 (pool), and Scr ASOs transfection in MM1s and NCI-H929 cells after 12 hr of treatment with 10 mM Nutlin-3a; Gapdh was internal loading
control and densitometric analysis was reported ±SD (E). (F) MDM2 mRNA expression normalized for GAPDH mRNA expression in MM1s and NCI-H929 cells
miRNAs or Scr transfected after Nutlin-3a treatment (6–12 hr) ±SD. (G) miRNAs predicted to interact with HDM2 gene in several consensus binding sites (XXX) at
its 30UTR, according to ‘‘in silico’’ RNA-22 prediction software. Luciferase assay showing decreased luciferase activity in cells cotransfected with pGL3-MDM2-
30UTR and miR-192, 194, 215, and Scr sequence. See also Figure S4. All experiments were performed in triplicate ±SD. (H) MDM2 mRNA relative expression in
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miR-192, 194, and 215 Target MDM2 in Myeloma Cells3700 ± 950 mm3 [p < 0.01]). The most effective combination
was MI-219 plus miRs, where mice showed 5-fold reduced
tumor volumes (from 5390 ± 993 mm3 to 2100 ± 560 mm3
[p < 0.01]) and >93% reduction when compared with VE/Scr
treatment (Figure 5E). These findings demonstrate proof-of-
concept for in vivo therapy of MM using combined miRNAs
and an MDM2 pharmacological inhibitor.miR-192 and miR-215, by Antagonizing MDM2
Downregulation, Target IGF-1 and IGF1-R
Since our data demonstrate that miR-192, miR-194, and
miR-215 target MDM2, we sought to determine if MDM2
substrates could also be affected. IGF-1R is a known target
of MDM2 ubiquitin ligase function (Girnita et al., 2003; Froment
et al., 2008). Therefore, by targeting MDM2, miR-192, 194,
and 215 may indirectly influence the expression of IGF-1R.
In MM cells, IGF-1R and its ligand, IGF-1, are key factors in
regulation of PC migration into the bone marrow (Qiang
et al., 2004; Tai et al., 2003). We noted that in WT TP53 MM
cells, p53 re-expression was strongly associated with downre-
gulation of IGF-1R and IGF-1 (Figures S5A and S5B) com-
pared with mutant TP53 MM cells (Figures S5C and S5D).
We sought to determine the effect of miRNAs on IGF-1R
and IGF-1 expression through targeting MDM2. We found
that in the presence of miR-192, 215 but not miR-194,
IGF-1R and IGF-1 protein levels decreased, as determined
by western blot analysis (Figure 6A). Furthermore, inhibition
of endogenous miR-192/215, using antisense oligonucleotides,
combined with 24 hr of Nutlin-3a treatments increased both
IGF-1R and IGF-1 levels in MM1s cells (Figure 6B). This effect
was not seen with miR-194. To determine if the regulation of
IGF-1 does affect IGF1R in MM cells, we silenced IGF-1
and-observed upregulation of IGF-1R protein levels at 48
and 72 hr posttreatment (Figure 6C). This effect was clearly
different from that observed following miRNA transfection
(Figure 6A). We next tested whether miR-192 and 215 target
IGF-1R and IGF-1 directly by generating luciferase reporters
containing their 30 UTRs. Using Targetscan (Lewis et al.,
2003), Pictar (Krek et al., 2005), and RNA22 (Miranda et al.,
2006) searches, we identified several MREs for miR-192 and
miR-215 but not for miR-194 in the 30UTR of IGF-1R and
IGF-1R mRNAs (Figures 6D and 6E). Luciferase activity drop-
ped 40%–50% when these constructs were cotransfected into
MM1s cells with miR-192, 215 compared with miR-194 and
Scr (Figures 6D and 6E; Figures S5E–S5I). To determine if in
freshly isolated CD-138+ PCs these miRNAs could regulate
IGF-1 and IGF-1R expression, we transfected miR-192 and
215 (pool) into PCs of nine patients, and we performed immu-
nofluorescence analysis for IGF-1R and IGF-1 at 48 hr. We
observed a significant decrease in IGF-1R and IGF-1 protein
expression (Figures 6F and 6G). Transfection efficiency was
confirmed using RNA Fluorescent Oligo (Figure 6H). These
results indicate that miR-192 and miR-215 directly target
IGF-1R and IGF-1 in MM.CD138+ PCs from healthy, MGUS, andMM samples with determined by RT-PCR
of the 2– ctmethod. Kruskal-Wallis analysis assessed thatMDM2mRNA is differen
the Bartlett test P value (<0.01) (see Table S3). (I) Graphic of the negative Spearma
trend between log of MDM2 mRNA relative expression and log of miR-192 relati
CmiR-192 and 215 Block MM Migration and Invasion
In Vitro and In Vivo
Given the known role of IGF-I and IGF-1R as antiapoptotic factors
and in MM migration through endothelial barriers and bone
marrow stroma (Qiang et al., 2004; Tai et al., 2003), we sought
to determine if miR-192 and 215 interfere with the chemotactic
function of IGF-I and block migration and invasion of MM cells.
We first determined that miR-192 and 215 actions on the IGF-1
axis in MM affect both WT TP53 (MM1s) and mutant (RPMI-
8226) cell lines (Figure 7A) and that the downregulation of both
proteins critically affects S6 and AKT phosphorylation in these
cells. Next, we found that ectopic expression of miR-192 and
215 in NCI-H929 and RPMI-8226 IGF-1-treated cells was associ-
ated with significant decrease in cell adhesion (Figures S6A and
S6B), migration, and tissue invasion compared with Scr control.
To this end, we used an intraepithelial trans-well migration assay
with IGF-1 at various concentrations as attractant and two bone
marrow-derived stromal cells, HS-5 (fibroblast-like) and HS-27A
(epithelial-like) as cell layer. As shown in Figure 7B and
Figure S6C, IGF-1 (50 ng/ml) stimulated migration of MM cells,
MM1s, and RPMI-8226. To further examine the role of miRNA-
192, 215, and 194 in MM cells, we investigated the effect of these
miRNAs onmigration in vivo, using a previously described homing
model (Roccaro et al., 2009). Nine NOD-SCID mice (for each
group) were intravenously injected with 8 3 106 of pre-miRNA-
192-, 194-, and 215- or Scr probe-transfected GFP+/Luc+MM1S
cells. One week later, mice were injected intravenously every
week for 4 weeks with an individual miRNA or Scr dissolved in
PBS (10 mg for eachmouse). After 5 weeks, the homed and prolif-
erated tumors were markedly suppressed in miRNA-treated mice
compared with Scr-transfected MM cells (p < 0.01) (Figure 7C).
At 5 weeks postinjection, we first noted reduced tumor progres-
sion, by bioluminescence imaging (Figure 7D). Mice injected
with Scr-transfected MM1s in addition to serial intravenous injec-
tion with Scr showed significant tumor growth, but tumor burden
was significantly reduced in mice injected with pre-miR-194 and
was nearly nonexistent in mice injected with either pre-miR192
or pre-miR-215 (Figures 7C and 7D). In addition, through FACS
analysis using human CD-138+ antibody, we analyzed bone
marrow engraftment of these cells in injected NOD-SCID mice.
We confirmed that Scr-treated mice showed bone marrow
engraftment of 25% ± 15% of MM1s cells versus 4% ± 2% for
miR-192 and 2% ± 2% for miR-215 animals (Figure 7E). The
in vivo action of miR-194 was less effective, 12% ± 3% of bone
marrow engraftment MM1s cells compared with miR-192 and
215but still higher than theScr control (Figure7E). Thesedata indi-
cate that miR-192, 215 but also miR-194 have therapeutic poten-
tial not only by affecting proliferation rates in MM cells but also by
affecting the homing and migration ability of MM cells.The Promoter Region of the miR-194-2-192 Cluster
is Hypermethylated in MM Cell Lines
During Nutlin-3a treatment of primary CD-138+ PCs from MMs
without TP53 deletion, we noted that p21 activation, as well as. Each data sample was normalized to the endogenous reference ACTIN by use
tially expressed among the healthy andMGUS samples vsMMPCs samples of
n correlation coefficient (r =0.698) corresponding to a decreasingmonotonic
ve expression (p < 0.001, N = 33).
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Figure 5. miR-192, 194, and 215 Increase Sensitivity to MI-219 In Vitro and In Vivo by Targeting MDM2
(A) Effects of miR-192, 194 and 215 on endogenous p53, p21, and MDM2 levels (western blots) in MM1s cells treated with MI-219 at different concentrations.
Densitometric analysis for p53 in untreated cells and for p53 and MDM2 protein levels in 2.5, 5, and 10 mM MI-219-treated cells is reported (B). All experiments
were performed in triplicate ±SD.
(C) Apoptotic effect at different concentrations and time points for each miRNA-transfected cells was assessed by caspase-3 activation assay ±SD.
(D) Apoptosis associated with the pool of these miRNAs upon MI-219 treatment (24 hr) at different concentration (2.5–10 mM) was evaluated by Annexin V.
All experiments were performed in triplicate ±SD.
(E) Gfp/Luc + MM1s cells were injected subcutaneously into the flanks of nude mice; at 3 weeks postinjection, mice with comparable tumor sizes were selected
for treatment (untreated). In vivo confocal imaging of GFP+/Luc+MM cells engrafted in athymic nu/numice after 2 weeks of combined treatment with oral MI-219
or vehicle (VE) plus pre-microRNA pool or Scr sequence directly into the tumors. Graphic represents the mean of tumors value (mm2) before (3 weeks) and after
the treatment (3+2 weeks) ±SD.
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Figure 6. miR-192-215 Regulate IGF-1 and IGF1-R Expression in MM Cells
(A and B)Western blot showing IGF-1R and IGF-1 expression after miR-192 andmiR-215 transfection using pre (A) and ASOs (B) formiR-192, 215, 194, and Scr in
MM1s cells treated for 12 hr with Nutlin-3a. Densitometric analysis is reported. See also Figure S5.
(C) Western blots after IGF-1 knockdown in MM1s (si-RNA) using anti-IGF-1R, IGF-1, and Gapdh antibodies.
(D and E) miRNAs predicted to interact with IGF-1 and IGF-1R gene at their 30UTR, according to ‘‘in silico’’ Target Scan (IGF-1) and RNA-22 (IGF-1R) prediction
software (see also Figure S5). Luciferase assay showing decreased luciferase activity in MM1s cells cotransfected with pGL3-IGF-1-30UTR (D) or pGL3-IGF-1R-
30UTR (full) (E) andmiR-192, 194, 215, or Scr. Deletion of six bases in all putative consensus sequences on IGF-1-30UTR abrogates these effect (Del) (D). See also
Figure S5. Bars indicate relative luciferase activity ±SD. All experiments were performed in triplicate.
(F and G) Immunofluorescence using anti-IGF-1R (F) and anti-IGF-1 (G) in red and blue nuclear DNA, from CD-138+ PCs from nine MM patients transfected with
miR-192 and miR-215 (pool) or Scr and intensity of the signal was assessed ±SD.
(H) The efficiency of the transfection in the nine samples was evaluated using fluorescent double-strand RNA oligos.
Scale bars indicate 25 mM.
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miR-192, 194, and 215 Target MDM2 in Myeloma Cellsre-expression of the three miRNAs, was consistent but not
uniform in all samples analyzed. Possibly mechanisms other
than alterations to the TP53 gene could influence the sensitivity
to MDM2 molecular inhibitors. In seeking an explanation for
the lack of expression of these miRNAs in MMs, we noted that
the genes for these miRNAs are located in chromosomal regions
in MM that are normally characterized by chromosome gain andCtranslocations rather than deletions (Fonseca et al., 2009). We
then explored the methylation status in the promoter of the
miR-194-2-192 cluster. By combined bisulfite restriction anal-
ysis (COBRA), we detected hypermethylation of the promoter
region of this cluster (Region R) (Figure S7A) in MM cell lines
(Figure S7B). Furthermore, treatment of MM cell lines with
a demethylation agent (Azacytidine) increased the expressionancer Cell 18, 367–381, October 19, 2010 ª2010 Elsevier Inc. 377
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Figure 7. miR-194, 215, and 194 Block Invasion Ability of MM Cells
(A) MM1s and RPMI-8226 cells (pre-miRNA-192, 194, 215, Scr-transfected) were harvested 72 hr after transfection.Whole-cell lysateswere immunoblotted using
IGF-1, IGF-1R, pS6, S6, p-Akt, Akt, and Gapdh antibodies; Scr sequence and miR-194-transfected cells served as controls. The experiments were performed in
triplicate.
(B) Intraepithelial migration assay in MM cells miRNAs transfected using HS-5 cells at different concentrations of IGF-1 as attractant. Bars indicate relative fold
change of migration compared with the control ±SD. See also Figure S6.
(C and D) In vivo confocal imaging. GFP+/Luc+ MM1s cells (8 3 106) were transfected using either pre-miRNA-192, -194, 215, and Scr RNA oligos and then
injected intravenously into mice immediately after transfection. After 1 week, the mice were injected intravenously with miRNAs (10 mg) once a week for 4 weeks,
and the bioluminescence intensity was assessed before every injection (C). (D) Representative bioluminescence imaging (BLI) after 5 weeks from the injection.
(E) Bone marrow cells from the mice used for the experiment were isolated and human CD-138 positive cells (engrafted cells) were detected using anti-CD-138
antibody by flow cytometry (P2 fraction).
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miR-192, 194, and 215 Target MDM2 in Myeloma Cellsof these miRNAs in WT TP53 MM cell lines (Figure S7C). Re-
expression of the SOCS-1 gene, known to be silenced by hyper-
methylation in MM cells (Galm et al., 2002), served as internal
control.
DISCUSSION
Complex cytogenetic abnormalities and numeric chromosomal
aberrations occur in virtually all multiple myeloma, and in most,
if not all, cases of MGUS (Kuehl and Bergsagel, 2002). Paradox-
ically, mutations and/or deletion of TP53 occur in only a small
percentage of intramedullary MMs and not at all in MGUS
(Chng et al., 2007). Several reports (Teoh et al., 1997; Quesnel
et al., 1994) and our data (Figure 4E) suggest that MDM2 overex-
pression in MMs, but not its gene amplification (Quesnel et al.,
1994), could be responsible for p53 inactivation in cells retaining
functional p53 pathways. This supports the idea that induction of378 Cancer Cell 18, 367–381, October 19, 2010 ª2010 Elsevier Inc.p53 in this setting might be a suitable treatment for MM. There
have been a few reports concerning microRNA deregulation in
MM and although not all reported findings were in agreement,
they confirmed that such deregulation is important in MM path-
ogenesis (Pichiorri et al., 2008; Roccaro et al., 2009; Lionetti
et al., 2009; Gutie´rrez et al., 2010). Here, we studied the role of
miRNAs in the p53 apoptotic pathway upon nongenotoxic acti-
vation of p53 in MM cells, using small molecular inhibitors of
MDM2 (Nutlin-3a, MI-219). Upon p53 activation, we identified
two related microRNA clusters located in regions considered
important for MM (miR-194-2-192 at 11q13.1 and miR-194-1-
215 at 1q41.1) (Fonseca et al., 2009). Furthermore, the knowl-
edge that miRNAs coming from the same cluster can reinforce
their action on the same cellular pathways (Garofalo et al.,
2009; Ventura et al., 2008) led us to study the molecular mecha-
nisms associated with activation of the p53 pathway by these
miRNAs. Through characterization of the miR-194-2-192 cluster
MI-219
Mdm-2
p53
mRNA degradation
P53 up-regulation
p21 up-regulation
Go/G1 arrest
Increase of apoptosis
p53
Nutlin-3a
Block of
Mdm2-p53
interaction
p53 up-regulation
miR-194
miR-192
miR-215
AAAAA
MDM2
AAAAA
IGF-1R
IGF-1
IGF-1 axis down regulation
Arrest of mobility and invasion
Figure 8. miR-192, 215, and 194 Impair the p53/MDM2 Autoregulatory Loop
Model to illustrate the possible role of miR-192, 194, and 215 in control of MDM2 and IGF-1/IGF-1R pathways in MM cells. See also Figure S7.
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miR-192, 194, and 215 Target MDM2 in Myeloma Cellspromoter region and definition of a noncanonical p53 consensus
site, we have shown that these miRNAs are direct p53 targets. In
patient samples, the expression of these miRNAs changed
during transition from normal PC, via MGUS to intramedullary
MM; these miRNAs were significantly downregulated in a cohort
of newly diagnosed MMs versus MGUS; miR-192, 215, and 194
enhanced colony suppression, cell-cycle arrest, or apoptosis in
a p53-dependent manner. We also noted, as in the case of
KMS28BM cells, that their biological action could be associated
with the MDM2 status in MM cells. The short half-life of MDM2
protein (Marine et al., 2010) and difficulties in analyzing its protein
expression in MM cells without p53 activation led to the demon-
stration that the effect of these miRNAs on MDM2 was clearly
detectable after treating WT TP53MM cells with combined Nut-
lin-3a and ectopic expression of the miRNAs. In fact, we
observed that in treated cells with enforced expression of these
miRNAs MDM2 was dramatically downregulated at protein and
mRNA levels and this downregulation was inversely associated
with higher p53 expression and p21 activation (Figures 4A–4C).
Luciferase assays using plasmids harboring the MDM2 30UTR
sequence strongly confirmed that MDM2 is the direct target of
these miRNAs. In a subset of newly diagnosed MMs, elevated
levels of MDM2 mRNA were inversely associated with miR-192
expression. We proved, in vivo and in vitro, that the combination
of these miRNAs with p53 pharmacological activator (MI-219),
leading to MDM2 downregulation and subsequent p53, p21,
and Puma upregulation, could be a successful therapeutic
strategy. In fact, it produced anti-tumor results that could not
be achieved solely by increasing the drug concentration. We
also found that miR-192 and miR-215 expression, by overriding
MDM2 ubiquitination of IGF-1R (Girnita et al., 2003; Froment
et al., 2008), directly targets the IGF-1 axis in MM cells, control-
ling mobility and invasive properties of MM cells in vitro and
in vivo. We propose a model in which these miRNAs are (1) regu-
lators of the autoregulatory loop, increasing the window of time
between p53 apoptotic action and p53 degradation by MDM2;
and (2) at the same time targeting the IGF axis, antagonizing
the MDM2 ubiquitin ligase function on IGF-1R (Figure 8).
The hypermethylation status in the promoter of themiR-194-2-
192 cluster in MM cell lines could support the hypothesis that the
transition from MGUS to MM is favored by clonal selection of
cells with aberrant promoter methylation of the miR-194-2-192Ccluster. This could be associated with a decreasing ability of
p53 to downmodulate MDM2 expression thus tipping the regula-
tory balance in favor of MDM2 in MM cells. This proposed model
(illustrated in Figure S7D) will require further investigation.
Of note, monoallelic deletion of TP53 in MM, which often
seems to occur without mutation on the other allele, is associ-
ated with an extremely poor prognosis (Chng et al., 2007). This
supports the idea that a 2-fold decrease in TP53 gene content
is associated with tumor progression, which supports the
hypothesis that a partial lack of expression of these miRNAs in
MMs could create a p53 imbalance with direct biological conse-
quences.
In summary, our results have defined a mechanism of p53
regulation through miRNAs acting on MDM2 expression,
providing the basis for the development of miRNA-targeted ther-
apies for MM, as illustrated in Figure 8.EXPERIMENTAL PROCEDURES
Collection of Primary Cells
Thirty-three newly diagnosed primary MM samples, 14 primary samples from
monoclonal gammopathy of undetermined significance (MGUS), and 5primary
samples from healthy donors were obtained from bone marrow aspirates.
Written informed consent was obtained in keeping with institutional policies
(IRB-approved procurement protocol (2000C0247) at Ohio State University
and The University of Turin GIMEMA-MM-03-05, N. EUDRACT 2005-
004745-33). Three of the five healthy PCs used were purchased from AllCells
LLC (Emeryville, CA).Luciferase Assays
MM1s cells were cotransfected with 1 mg of pGL3 firefly luciferase reporter
vector (see luciferase reporter vector method in Supplemental Information),
0.1 mg of the phRL-SV40 control vector (Promega), and 100 nMmiRNA precur-
sors (Ambion) using nucleoporation (LONZA) Cell Line Nucleofector Kit V as
previously described. Firefly and Renilla luciferase activities were measured
consecutively by using the Dual Luciferase Assay (Promega) 24 hr after trans-
fection. Each reporter plasmid was transfected at least twice (on different
days) and each sample was assayed in triplicate.Mouse Experiments
All animals were housed in the Ohio State University animal facility and the
experiments with live animals were approved by our institute animal
committee (IACUC 2007-A0146) and conducted following the Ohio State
University animal policy in accordance with NIH guidelines.ancer Cell 18, 367–381, October 19, 2010 ª2010 Elsevier Inc. 379
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miR-192, 194, and 215 Target MDM2 in Myeloma CellsGFP/Luc + MM1s cells (1 3 106) were suspended in 0.10 ml of extracellular
matrix gel (BD Biosciences) and the mixture was injected subcutaneously into
the right flank athymic nu/nu mice. Three weeks after injection, mice with
comparable size tumors were treated for 2 weeks with a combination of oral
dose of MI-219 (200 mg/kg) or vehicle, once a day for 14 days and miRNAs
or scrambled sequence oligos (10 mg) (Ambion), was injected directly into
the tumors once a week for 2 weeks. For the NOD-SCID engraftment model
Luc+/GFP+ MM.1S cells (8 3 106/mouse) were injected into the tail vein of
SCID mice. Treatment started 7 days from tumor cell inoculation, by weekly
intravenous injections of miRNAs or scrambled sequence. RNA oligos
(Ambion) (10 mg) for four cycles (4 weeks total). For more details, see in vivo
experiments in Supplemental Information.
Transfection Method for Primary Cells and MM Cell Lines
CD-138+ PCs obtained from new diagnosed MM patients and isolated as
previously described were transfected by using nucleoporation (LONZA) Cell
Line Nucleofector Kit V (Cat#VCA-1003). MM1s, NCI-H929 cell lines were
transfected by using nucleoporation (LONZA) Cell Line Nucleofector Kit V
(Cat#VCA-1003). Instead for U266, KMS-28BM, and RPMI-8226, Cell Line Nu-
cleofector Kit C (Cat#VCA-1004) was used. Specifically for primary cells
1 3 106 CD-138+ PCs were resuspended in 100 ml V solution and 100 nM
miRNA precursors (Ambion) was used for the transfection reaction. For more
details, see transfection method for primary cells in Supplemental Information.
Target Screening
In this study, we used three publicly available search engines for target predic-
tion to obtain the putative targets: TargetScan (Release 2.1), http://genes.mit.
edu/targetscan, Pictar, http://pictar.bio.nyu.edu, and Rna22, http://cbcsrv.
watson.ibm.com/rna22_targets.html. For RNA22 predicted sites, we consid-
ered only the heteroduplex with a folding energy > 27 Kcal/mol (Figures
S8B–S8E) because we were not able to confirm by luciferase assay the
interactions between target gene and miRNAs with a folding energy less
that 27 Kcal/mol (data not shown).
ACCESSION NUMBERS
The microarray data have been deposited in the Array Express database,
www.ebi.ac.uk/arrayexpress (accession number E-TABM-1037 and
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Supplemental Information includes Experimental Procedures, references,
seven figures, and three tables and can be found online at doi:10.1016/j.ccr.
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